Bolar exemption
Also called Bolar safe harbor, regulatory review safe harbor, 271(e)(1) safe harbor
Bolar exemption refers in the United States to the safe harbor in 35 U.S.C. 271(e)(1) for specified acts involving a patented invention, subject to statutory limits, solely for uses reasonably related to developing and submitting information under qualifying federal law1.
What the US statute covers
Section 271(e)(1) makes it noninfringing to make, use, offer to sell, or sell a patented invention within the United States, or to import it into the United States, solely for uses reasonably related to developing and submitting information under a federal law regulating the manufacture, use, or sale of drugs or veterinary biological products, subject to the statute's exclusion1.
The exclusion applies to a new animal drug or veterinary biological product, as those terms are used in the Federal Food, Drug, and Cosmetic Act and the Act of March 4, 1913, if the product is manufactured primarily using recombinant DNA, recombinant RNA, hybridoma technology, or another process involving site-specific genetic manipulation techniques1.
How Merck applied the reasonable-relation requirement
In Merck KGaA v. Integra Lifesciences I (2005), the US Supreme Court said a use is reasonably related at least when a drugmaker has a reasonable basis for believing that a patented compound may produce a particular physiological effect through a particular biological process and uses it in research that, if successful, would be appropriate for inclusion in an FDA submission2.
The US Supreme Court in Merck (2005) also held that leaving the experiment's data out of an FDA submission does not, by itself, make use of the compound in that experiment infringing2.
The separate EU provision for human medicines
| Provision | Scope and legal effect |
|---|---|
| United States: section 271(e)(1) | The specified acts are not infringement if they are solely for qualifying uses under the federal-law test and the statutory exclusion does not apply1. |
| European Union: Directive 2001/83/EC, Article 10(6) | For medicinal products, Article 10(6) treats the necessary studies and trials for the purpose of applying Article 10(1) through (4) and the consequential practical requirements as activities that do not conflict with patent rights or supplementary protection certificates3. |
Questions people ask
Check a product
FTO Search AI Agent
Turn product details into a reviewable search strategy, focused patent candidates, and evidence your IP team can take further.
Run FTO SearchIs the US safe harbor limited to generic drug research?
No, the US Supreme Court in Merck (2005) held that section 271(e)(1) is not confined to research relevant to filing an abbreviated application for generic drug approval; the statutory reasonable-relation requirement and other limits still apply1,2.
Can US preclinical studies qualify?
Yes, the US Supreme Court in Merck (2005) said that use of patented compounds in preclinical studies can qualify when there is a reasonable basis to believe the experiments will produce the types of information relevant to an investigational new drug application or a new drug application, subject to the statutory limits1,2.
Does the EU provision address supplementary protection certificates as well as patents?
Yes. Article 10(6) covers both patent rights and supplementary protection certificates for medicinal products with respect to the necessary studies and trials for the purpose of applying Article 10(1) through (4) and the consequential practical requirements3.
How it connects
Go from the term to the task
Read how the method works, run it on your own product or idea, then try a free tool.
- 01 / How-toHow to run a freedom-to-operate analysisScope, search, claim review and the report counsel will ask for.Read
- 02 / AI agentFTO Search AI AgentTurn product details into a reviewable search strategy, focused patent candidates, and evidence your IP team can take further.Run it